This HTML5 document contains 87 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/chemspider/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/chebi/
n6http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/bindingdb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/pubchem-substance/
n16http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00224/identifier/drugbank/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00224
rdf:type
n3:Drug
n3:description
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
n3:dosage
n8:271B5FFB-363D-11E5-9242-09173F13E4C5 n8:271B5FFC-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1.8 (± 0.4) hours
n3:indication
Indinavir is an antiretroviral drug for the treatment of HIV infection.
n3:manufacturer
n7:271B5FF5-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00224 n27:DB00224
dcterms:title
Indinavir
adms:identifier
n11:5362440 n12:46506442 n17:0006-0570-62 n18:PA449977 n19:C07051 n20:4515036 n21:DB00224 n22:517 n23:5898 n26:Indinavir
n3:mechanismOfAction
Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
n3:packager
n7:271B5FEE-363D-11E5-9242-09173F13E4C5 n7:271B5FEF-363D-11E5-9242-09173F13E4C5 n7:271B5FEC-363D-11E5-9242-09173F13E4C5 n7:271B5FED-363D-11E5-9242-09173F13E4C5 n7:271B5FF2-363D-11E5-9242-09173F13E4C5 n7:271B5FF3-363D-11E5-9242-09173F13E4C5 n7:271B5FF0-363D-11E5-9242-09173F13E4C5 n7:271B5FF1-363D-11E5-9242-09173F13E4C5 n7:271B5FF4-363D-11E5-9242-09173F13E4C5
n3:patent
n9:6689761 n9:2081970 n9:5413999
n3:routeOfElimination
Less than 20% of indinavir is excreted unchanged in the urine.
n3:synonym
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide Indinavir
n3:toxicity
Symptoms of overdose include myocardial infarction and angina pectoris.
n13:hasAHFSCode
n24:08-18-08-08
n3:foodInteraction
Avoid excessive or chronic alcohol use. Take with a full glass of water. Avoid taking with grapefruit juice Take on empty stomach: 1 hour before or 2 hours after meals.
n3:proteinBinding
60%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Indinavir.htm
n29:hasConcept
n30:M0028961
foaf:page
n16:indinav.htm n31:indinavir.html
n3:IUPAC-Name
n4:271B6001-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6007-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6006-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6003-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6004-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6005-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6017-363D-11E5-9242-09173F13E4C5 n4:271B5FFF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6019-363D-11E5-9242-09173F13E4C5 n4:271B6000-363D-11E5-9242-09173F13E4C5 n4:271B5FFD-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5FFE-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:J05AE02
n3:H-Bond-Acceptor-Count
n4:271B600D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B600E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6008-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6009-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B600B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B600A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B600C-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed
n3:affectedOrganism
Human Immunodeficiency Virus
n3:casRegistryNumber
150378-17-9
n3:containedIn
n28:271B5FF7-363D-11E5-9242-09173F13E4C5 n28:271B5FF8-363D-11E5-9242-09173F13E4C5 n28:271B5FF6-363D-11E5-9242-09173F13E4C5 n28:271B5FF9-363D-11E5-9242-09173F13E4C5 n28:271B5FFA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6013-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6015-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6016-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6018-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6012-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6011-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6014-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6002-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B600F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6010-363D-11E5-9242-09173F13E4C5